CJC-1295 and Sermorelin Together: What Is Known

CJC-1295 and Sermorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · 3 Oct 2026 · DisclosureUpdated 3 Oct 2026

GHRH analogNot FDA approved · research chemicalCJC-1295CJC-1295, a GHRH analog; in healthy adults a single injection produced dose-dependent rises in mean plasma GH of 2- to 10-fold and in IGF-I of 1.5- to 3-fold.^[4]Growth hormoneGHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.^[16]Growth hormone

Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 13 results, 2 Oct 2026).

Sermorelin is not FDA approved, and we have no sourced data on combining it with CJC-1295.

Each component

Side by side

Showing 5 of 13 fields where the two differ. Class, Category, PCAC vote, Jul 2026, WADA, Anti-doping detection, Half-life, Evidence strength, Human studies we summarised are the same or both unknown.

Field	CJC-1295	Sermorelin
Class	GHRH analog	GHRH analog
Also called	CJC, mod GRF, GRF 1-29	—
Category	Growth hormone	Growth hormone
FDA status	Not FDA approved · research chemical	Compounded by prescription
PCAC vote, Jul 2026	Not on the Jul 2026 agenda	Not on the Jul 2026 agenda
WADA	Prohibited by WADA (S2.2.4)CJC-1295 is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.	Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.
Anti-doping detection	A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973 Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524	A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973 Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
Half-life	No published half-life foundPubMed search, 2 Oct 2026	No published half-life foundPubMed search, 2 Oct 2026
Evidence strength	Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 2006, PMID 16352683	Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256
Human studies we summarised	4 human (1 randomized or controlled) of 7 summarised	4 human (1 randomized or controlled) of 7 summarised
Typical study doses	Four ascending single doses (first study); two or three weekly or biweekly doses (second study), single, weekly or biweeklyThe Journal of clinical endocrinology and metabolism 2006, PMID 16352683 60 or 90 microg/kg CJC-1295 (single injection), singleThe Journal of clinical endocrinology and metabolism 2006, PMID 17018654 2 microg CJC-1295, every 24, 48 or 72 hAnimal · mouse · American journal of physiology. Endocrinology and metabolism 2006, PMID 16822960	0.5 mg (low) and 1 mg (high) GHRH-(1-29), twice dailyThe Journal of clinical endocrinology and metabolism 1992, PMID 1379256 100 mcg each of GHRP-6, GHRP-2 and sermorelin, three times dailyAmerican journal of men's health 2017, PMID 28830317 2 mg GHRH (1-29), nightly self-injectionMetabolism: clinical and experimental 1997, PMID 9005976
Vial sizes sold	2 mg, 5 mg, 10 mg	2 mg, 5 mg, 9 mg, 15 mg
US searches per month	60,500 · +49% searches	165,000 · Flat YoY

Related tools

CJC-1295 vs Sermorelin

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

ComparisonSermorelin vs CJC-1295

What people search

sermorelin cjc 129570/mo
sermorelin and cjc 129570/mo
cjc 1295 sermorelin50/mo
cjc 1295 and sermorelin50/mo
cjc 1295 with sermorelin40/mo
sermorelin with cjc 129530/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
4Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
5Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
6Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
7PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
9Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
10Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
11Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
12PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
13PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
14PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
15PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
16Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026

Found an error? Report a correction.